Cerevel Therapeutics (CERE) Revenue & Revenue Breakdown
Cerevel Therapeutics Revenue Highlights
Cerevel Therapeutics Revenue by Period
Cerevel Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | -100.00% |
2015-08-31 | $2.72M | 13.14% |
2014-08-31 | $2.40M | -54.15% |
2013-08-31 | $5.24M | -2.38% |
2012-08-31 | $5.37M | 100.00% |
2001-01-01 | - | - |
Cerevel Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | - | -100.00% |
2023-12-31 | $8.25M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | -100.00% |
2016-05-31 | $1.42M | 303.13% |
2016-02-29 | $351.00K | -62.74% |
2015-11-30 | $942.00K | 10.56% |
2015-08-31 | $852.00K | -24.27% |
2015-05-31 | $1.13M | 227.99% |
2015-02-28 | $343.00K | -14.25% |
2014-11-30 | $400.00K | 17.65% |
2014-08-31 | $340.00K | -57.82% |
2014-05-31 | $806.00K | 62.83% |
2014-02-28 | $495.00K | -35.12% |
2013-11-30 | $763.00K | -14.94% |
2013-08-31 | $897.00K | -33.80% |
2013-05-31 | $1.35M | 32.20% |
2013-02-28 | $1.02M | -47.86% |
2012-11-30 | $1.97M | 68.90% |
2012-08-31 | $1.16M | 1.39% |
2012-05-31 | $1.15M | -131.10% |
2012-02-29 | $-3.69M | - |
Cerevel Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
BPMC | Blueprint Medicines | $249.38M | $138.16M |
TVTX | Travere Therapeutics | $145.24M | $54.12M |
HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
SWTX | SpringWorks Therapeutics | $5.45M | $21.01M |
IGMS | IGM Biosciences | $2.13M | $497.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
NUVL | Nuvalent | - | - |
DAWN | Day One Biopharmaceuticals | - | $8.19M |
CERE | Cerevel Therapeutics | - | - |
TERN | Terns Pharmaceuticals | - | - |
VTYX | Ventyx Biosciences | - | - |
MLYS | Mineralys Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
CERE Revenue FAQ
What is Cerevel Therapeutics’s yearly revenue?
Cerevel Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CERE's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Cerevel Therapeutics’s quarterly revenue?
Cerevel Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $8.25M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). CERE's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Cerevel Therapeutics’s revenue growth rate?
Cerevel Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.